AGEAS

HEALTH CHECK

16/05/24 -"As we have consistently argued over the last 3 years, Health stocks (ex Pharma) are long on growth promises and short on delivery. The gap stems from the fact that delivery hinges on buying the next ..."

PDF page sample
Pages
48
Language
English
Published on
16/05/24
Download
You may also be interested by these reports :
11/11/26
Swiss Life’s 3Q figures were mixed, in our view. While recurring fee income growth at Asset Managers was strong in Q3, group-level fee and commission ...
11/11/26
UNIQA will publish its 3Q26 results on 20 November, only a few days before its Capital Markets Update in London on 25 November. We continue to ...
11/11/26
Swiss Life released its 3Q26 results. While fee and commission income growth accelerated in Q3, this was driven by the first-time consolidation of ...
11/11/26
We have updated our forecasts following the publication of Hannover Re’s 3Q results. Hannover Re will present its outlook for 2027 and the medium ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO